Immunotherapy before surgery shows promise for mesothelioma patients

NCT ID NCT03918252

Ongoing Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) before surgery is safe and feasible for people with resectable malignant pleural mesothelioma. About 30 adults with epithelial or biphasic mesothelioma will receive the drugs, then undergo surgery, followed by a year of maintenance nivolumab. The goal is to see if this approach can shrink tumors and improve outcomes without causing major delays in surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pleural mesothelioma mesothelioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MESOTHELIOMA

Contacts and locations

Show contact details

Locations

Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine

Baltimore, Maryland, 21201, United States
Johns Hopkins University

Baltimore, Maryland, 21287, United States
University of Texas M.D. Anderson Cancer Center

Houston, Texas, 77030, United States